Welcome to SN Connect, the new gold standard for HCP-focused media.

Latest News

SEE MORE   

Exciting updates in cancer research and standards of care brought to you in collaboration with leading experts in oncology.

    1. Events

  1. Addressing Disparities

Elahere for Ovarian Cancer: Prevention, Detection & Management of Ocular Adverse Events

The Latest in Managing Anemia for Patients With Myelodysplastic Syndrome

Neoadjuvant Immunotherapy in Stage III Melanoma: Improved Outcomes with Response-Driven Approach

Latest News

Exciting updates in cancer research and standards of care brought to you in collaboration with leading experts in oncology.

    1. Events

  1. Addressing Disparities

Welcome to SN Connect

SN Connect: A New Destination for Physician Education

SurvivorNet Connect is a resource for healthcare providers. It's so important for those who work in the industry to have access to the latest in cancer research, treatment approaches, side effect profiles, and so much more. At SurvivorNet, we strive to bring reliable information about cancer care to patients and their... Read More

Viewpoints

Elahere: A Practice-Changing Option for Platinum-Resistant, FRα-Positive Ovarian Cancer

Liz Neporent

Unprecedented Progression-Free Survival for ALK-Positive Non-Small Cell Lung Cancer Using Lorbrena — What the New Research Means for Patients

Dr. Douglas Swords

When to Order Immunohistochemistry Testing: With Tailored Therapies for HER2-Positive Cancers, IHC is More Relevant for More Patients

Liz Neporent

Criteria and Considerations for Using Newly FDA-Approved Lifileucel in Advanced Melanoma

Liz Neporent

Research Shows the Best Way to Discuss Clinical Trials With Patients & Boost Trust, Confidence

Liz Neporent

Study Raises Clinical Considerations for Strategic Immunotherapy Use in Metastatic Cancer Care

Kavontae Smalls

Elahere: A Practice-Changing Option for Platinum-Resistant, FRα-Positive Ovarian Cancer

Liz Neporent

Unprecedented Progression-Free Survival for ALK-Positive Non-Small Cell Lung Cancer Using Lorbrena — What the New Research Means for Patients

Dr. Douglas Swords

When to Order Immunohistochemistry Testing: With Tailored Therapies for HER2-Positive Cancers, IHC is More Relevant for More Patients

Liz Neporent

Criteria and Considerations for Using Newly FDA-Approved Lifileucel in Advanced Melanoma

Liz Neporent

Research Shows the Best Way to Discuss Clinical Trials With Patients & Boost Trust, Confidence

Liz Neporent

Study Raises Clinical Considerations for Strategic Immunotherapy Use in Metastatic Cancer Care

Kavontae Smalls

Improving Access to Care

How to Reduce Cancer Mortality By Dramatic 20%: ASCO Leader Says Focus Should Be on Improving Access to Existing Standard of Care & Prevention

Every year, thousands of experts and advocates in cancer treatment and research converge for the American Society of Clinical Oncology (ASCO) conference, which is the largest cancer conference of the year. SurvivorNet sat down with ASCO CEO Dr. Clifford Hudis, who explained that one of the most powerful ways to make pr... Read More

SurvivorNet Staff

Clinical Updates

SEE MORE   

For HR+/HER2- Early-Stage Breast Cancer at Increased Risk of Recurrence, Kisqali Has Benefits: Study

Imfinzi Improves Overall & Progression-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer

A Powerful Tool: Integrating Venetoclax into CLL Management Improves Survival

Balversa's FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer

Treatment

Oncologists Weigh in on Optimal Use of CDK 4/6 Inhibitors as Adjuvant Therapy in Early Breast Cancer

For Women With Heavily-Treated Triple-Negative or HR+, HER2- Metastatic Breast Cancer, Padvec Shows Some Anti-Tumor Activity

Rytelo Gains FDA Approval for Lower-Risk Myelodysplastic Syndrome: Reducing Need For Blood Transfusions & Improving Quality of Life

Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval

Tepmetko Approval for NSCLC Mutation Underscores the Value of Genetic Testing

Clinical Updates

The Latest in Lung Cancer

Treatment

Practice-Changing Research Indicates Tagrisso (Osimertinib) Significantly Slows Progression for EGFR-Mutated Stage 3 Lung Cancer

A drug called osimertinib (brand name: Tagrisso) is showing even more promise in treating a specific type of lung cancer known as EGFR-mutated lung cancer. The latest trial results for the drug were presented at this year's American Society of Clinical Oncology (ASCO) conference, a major cancer conference held each spr... Read More

Dr. Sufana Shikdar University of Oklahoma's College of Medicine

Patient Care Updates

SEE MORE   

Nearly 50% Skip Prescribed Breast Cancer Meds — Physicians Should Focus on Education & Cutting Costs

New ASCO Guidelines Offer a Practice-Changing Approach for PIK3CA/AKT1/PTEN Metastatic Breast Cancer

Study: Physicians Should Prioritize Weight Management in Breast Cancer Care to Boost Survival Rates

Patient Care Updates

Addressing Disparities

SEE MORE   

Close the Gap 2024 - Addressing Disparities in Cancer Care & Improving Outcomes for Patients

Community Engagement & Resources are Key to ‘Closing the Gap’ on Racial Disparities in Cancer Care

Meeting the Needs of Black Caregivers

SurvivorNet Staff

Addressing Disparities

Our Mission

Our mission at SN Connect is to empower healthcare professionals by sharing insights from the world’s leading experts, providing essential resources, and hosting events that foster collaboration and knowledge exchange.

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider